Biomind Labs Inc.

What Biomind Labs Inc. does

Biomind Labs Inc. is a publicly traded, clinical-stage pharmaceutical company developing next-generation psychedelic-based drug candidates for neurological and psychiatric disorders. Founded in 2019 and headquartered in Toronto, Canada, the company is listed on the NEO Exchange (BMND), OTC Markets (BMNDF), and Frankfurt Stock Exchange (3XI), and maintains an office at the Cambridge Biomedical Campus in the United Kingdom. Its diversified pipeline comprises eight proprietary candidates (BMND01 through BMND09) targeting treatment-resistant depression, fibromyalgia, addictive disorders, chronic pain, morbid obesity, major depressive disorder, Alzheimer's disease, and Parkinson's disease. Lead candidate BMND08, a proprietary 5-MeO-DMT nano-formulation for Alzheimer's, is in Phase II trials and has reported 100% patient response and remission from depression, anxiety, and stress by week five; BMND01 is also Phase II, while BMND06 and BMND09 are Phase I.

The company's underlying technology is built around tailored drug delivery systems and proprietary nano-formulations applied to psychedelic molecules (5-MeO-DMT, psilocybin, DMT, MDMA, ibogaine), designed to control the time and place of drug release for specific therapeutic indications. Intellectual property consists of 19 patent applications derived from 8 priority documents across USPTO, PCT, and EPO jurisdictions, covering the full molecule-to-market lifecycle. Biomind pursues fast-track approvals and breakthrough therapy designations across the portfolio and has publicly aligned its strategy with the April 2026 U.S. federal executive order directing agencies to accelerate psychedelic research.

Biomind operates a pre-revenue business model with no commercialized products; its intended revenue stream is pharmaceutical product sales through traditional distribution channels (pharmacies, hospitals, clinical settings under prescription) following FDA/regulatory approval. End customers are patients with neurological and psychiatric conditions, served indirectly via healthcare providers and payors once products are approved. The company is led by CEO Alejandro Antalich, CFO Oscar León, CSO Paola Díaz Dellavalle, CLO Juan Presa, and Chairman Ravi Sood, with Harvard Medical School neurology expertise on the board. Current financial statements in the input reflect data integrity concerns, with reported EBITDA and net income figures inconsistent with a clinical-stage biotech at this scale.

Name

Biomind Labs Inc.

Legal name

Biomind Labs Inc.

Website

https://biomindlabs.com

Company type

Public

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Biomind Labs Inc. is a publicly traded clinical-stage pharmaceutical company developing proprietary psychedelic-based drug candidates for neurological and psychiatric disorders, including Alzheimer's, Parkinson's, treatment-resistant depression, and fibromyalgia, across an eight-asset pipeline.

Ownership category

akta.pro rank

Product category

Neurology & Psychiatry Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE), Formulation & Preclinical CMC Support (Nonclinical) (HLAGAFAL)

Keywords

• Psychedelic pharmaceuticals
• Neurological disorder treatments
• Clinical-stage biotech
• Drug delivery systems
• Central nervous system therapeutics

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Biomind Labs develops proprietary pharmaceutical compounds through clinical trials toward regulatory approval. Upon FDA/regulatory approval, the company will commercialize its drug candidates (BMND01, BMND08, etc.) for treatment of neurological and psychiatric disorders.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Biomind Labs develops a clinical-stage pipeline of proprietary psychedelic-based pharmaceutical formulations (BMND01 through BMND09) for the treatment of neurological and psychiatric disorders, including treatment-resistant depression, Alzheimer's, Parkinson's, fibromyalgia, addictive disorders, chronic pain, morbid obesity, and major depressive disorder. The products incorporate proprietary nano-formulations and tailored controlled-release drug delivery systems designed to provide fast-acting, patient-comfortable dosing. The company is advancing candidates through Phase I and Phase II clinical trials targeting FDA regulatory approval.

Product overview

Biomind Labs Inc. is a next-generation pharmaceutical company developing a portfolio of novel psychedelic-based drugs for neurological disorders. The company operates a diversified pipeline of clinical-stage drug candidates (BMND01 through BMND09) targeting treatment-resistant depression, fibromyalgia, addictive disorders, chronic pain, morbid obesity, major depressive disorder, Alzheimer's disease, and Parkinson's disease. The product portfolio includes proprietary formulations at various stages: Phase II (BMND01, BMND08), Phase I (BMND06, BMND09), pre-clinical (BMND03), and evaluation stages (BMND02, BMND05, BMND07). The company focuses on transforming biomedical sciences knowledge into fast-acting, controlled-release novel drugs using tailored drug delivery systems, with a commitment to personalized medicine and sustainable production for democratic access.

Differentiator

Problem solved

Functional benefit

Products and services

• BMND01 A proprietary psychedelic-assisted drug formulation in Phase II clinical trials for the treatment of Treatment-Resistant Depression, utilizing novel drug delivery mechanisms.
• BMND02 A proprietary drug formulation in the evaluation stage for the treatment of Fibromyalgia, utilizing novel drug delivery technology.
• BMND03 A proprietary drug formulation in pre-clinical development for the treatment of Addictive Disorders, utilizing novel psychedelic-based therapy approaches.
• BMND05 A proprietary drug formulation in the evaluation stage for the treatment of Chronic Pain, utilizing novel drug delivery systems.
• BMND06 A proprietary drug formulation in Phase I clinical trials for the treatment of Morbid Obesity, utilizing novel drug delivery mechanisms.
• BMND07 A proprietary drug formulation in the evaluation stage for the treatment of Major Depressive Disorder, utilizing novel psychedelic-assisted therapy approaches.
• BMND08 (5-MeO-DMT Nano-Formulation) A proprietary 5-MeO-DMT-based formulation in Phase II clinical trials for the treatment of Alzheimer's disease, demonstrating 100% patient response rate and 100% remission from depression, anxiety, and stress by week five in clinical trials. The company has developed a proprietary nano-formulation for enhanced delivery.
• BMND09 A proprietary drug formulation in Phase I clinical trials for the treatment of Parkinson's Disease, utilizing novel drug delivery technology.

Quantifiable outcome

• 100% patient response rate and 100% remission from depression, anxiety, and stress by week five in Alzheimer's patients (Phase 2 BMND08 trial)

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Mind Medicine (MindMed): Public psychedelic medicine biotech advancing LSD-based therapies (MM-120) for anxiety and ADHD, plus MDMA programs. Comparable on psychedelic CNS pipeline breadth, public listing, and clinical-stage regulatory strategy.
• atai Life Sciences: Public clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic therapies for mental health, with multiple programs including DMT and psilocybin derivatives. Highly comparable diversified psychedelic pipeline model to Biomind.
• GH Research: Clinical-stage pharmaceutical company developing 5-MeO-DMT (GH001) for treatment-resistant depression using proprietary inhaled and injectable delivery. Directly comparable to Biomind on lead molecule class (5-MeO-DMT), target indication overlap, and clinical-stage psychedelic CNS focus.
• Cybin: Public psychedelic therapeutics company advancing CYB003 (deuterated psilocybin) for MDD and CYB004 (DMT) for anxiety. Comparable psychedelic CNS pipeline, public listing, and proprietary formulation focus.
• Compass Pathways: Public psychedelic pharma developing COMP360 psilocybin therapy for treatment-resistant depression. Direct peer to BMND01 in TRD indication, with comparable clinical-stage pipeline, FDA regulatory pathway, and similar public-market capital structure.

Broad incumbents

• Axsome Therapeutics: Commercial-stage CNS biopharmaceutical company with approved products in depression and migraine (Auvelity, Sunosi). Comparable as a CNS-focused pharma pursuing novel mechanisms in depression and neurology, providing scale and execution benchmark.
• Sage Therapeutics: Established CNS-focused biopharmaceutical company (Zurzuvae approved for postpartum depression). Comparable on CNS specialty pharma positioning and innovative CNS mechanism focus, though at commercial stage with broader portfolio.

Emerging players

• BetterLife Pharma: Clinical-stage psychedelic and CNS therapeutics developer with BETR-001 (LSD derivative) and other candidates. Overlaps with Biomind on psychedelic CNS pipeline but at earlier clinical stage.
• Silo Pharma: Early-stage psychedelic and CNS-focused biotech developing novel drug delivery approaches for psilocybin and other compounds. Comparable in psychedelic CNS positioning but with smaller pipeline and earlier stage than Biomind.

Others

• MAPS PBC: Public benefit corporation focused on psychedelic research including MDMA-assisted therapy development. Adjacent comparable on psychedelic CNS advocacy and clinical development, though structured as a non-profit rather than commercial pharma.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biomind-labs-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biomind Labs Inc.